Background: In 1998 choline Adequate Intakes of 425 and 450 mg/d were established for nonpregnant and pregnant women, respectively. However, to our knowledge, no dose-response studies have been conducted to evaluate the effects of pregnancy or maternal choline intake on biomarkers of choline metabolism. Objective: We sought to quantify the effects of pregnancy and maternal choline intake on maternal and fetal indicators of choline metabolism. Design: Healthy pregnant (n = 26; 27 wk gestation) and nonpregnant (n = 21) women were randomly assigned to receive 480 or 930 mg choline/d for 12 wk. Fasting blood samples and placental tissue and umbilical cord venous blood were collected and analyzed for choline and its metabolites. Results: Regardless of the choline intake, pregnant women had higher circulating concentrations of choline (30%; P , 0.001) but lower concentrations of betaine, dimethylglycine, sarcosine, and methionine (13-55%; P , 0.001). Obligatory losses of urinary choline and betaine in pregnant women were ;2-4 times as high (P 0.02) as those in nonpregnant women. A higher choline intake yielded higher concentrations of choline, betaine, dimethylglycine, and sarcosine (12-46%; P 0.08) in both pregnant and nonpregnant women without affecting urinary choline excretion. The higher maternal choline intake also led to a doubling of dimethylglycine in cord plasma (P = 0.002). Conclusion: These data suggest that an increment of 25 mg choline/d to meet the demands of pregnancy is insufficient and show that a higher maternal choline intake increases the use of choline as a methyl donor in both maternal and fetal compartments. This trial was registered at clinicaltrials.gov as NCT01127022.
INTRODUCTION
Choline, which is a micronutrient commonly grouped with B vitamins, is required for the biosynthesis of phosphatidylcholine, which is the main component of cell membranes, and the formation of the cholinergic neurotransmitter acetylcholine. After its oxidation to betaine, choline is also a major dietary source of methyl groups, which can be transferred to DNA and histones in an S-adenosylmethionine-dependent reaction. DNA and histone methylation (ie, epigenetic modifications) can, in turn, exert lasting effects on gene expression (1) . The oxidation of choline also generates dimethylglycine (DMG) 5 and methylglycine (sarcosine) in a sequential demethylation manner as follows: choline / betaine / DMG / sarcosine. The methyl groups associated with these choline-derived methyl donors (ie, DMG and sarcosine) can be used in folate-mediated one-carbon metabolism for the biosynthesis of nucleotides and methionine (2) .
Pregnancy is associated with a higher demand for choline because of accelerated one-carbon metabolism and the formation of new membranes as cells undergo division (3) . Pregnancy caused a pronounced reduction of choline pools in rodents that consumed a normal feed-pellet diet (4) , which indicated that the need for this nutrient by the mother and the fetus may exceed the amount consumed by the mother and the amount produced by the endogenous pathway [ie, the phosphatidylethanolamine N-methyltransferase (PEMT) pathway]. Furthermore, the supplementation of the maternal rat diet with additional choline (;4 times the amount in normal feed pellets) leads to a significant enhancement of memory function of the adult offspring (5, 6 ) and substantially lessens aging-related memory decline (7, 8) . The long-lasting beneficial effects of maternal choline supplementation on cognitive function may arise, at least in part, from modifications of DNA methylation secondary to the use of choline as a methyl donor. Although few studies have addressed the adequacy of human choline intake during pregnancy, dietary choline intake (9) and midgestation maternal serum total choline (10) are inversely associated with the risk of having an infant with a neural tube defect.
In 1998 dietary choline recommendations in the form of Adequate Intakes (AIs) were established for the first time by the Food and Nutrition Board of the Institute of Medicine (11) . The choline AI for pregnant women of 450 mg choline/d is largely based on the AI for nonpregnant women (425 mg choline/d), which was extrapolated from a single study conducted in men and designed to prevent liver dysfunction (11) . An increment of 25 mg choline/d was added to the AI of nonpregant women to support fetal and placental growth and was largely based on animal data. Thus, additional studies that examine the effect of pregnancy and maternal choline intake on biomarkers of choline metabolism are needed to scientifically inform the development of dietary recommendations that optimize maternal health and fetal well-being.
The goals of this study were to quantify the effects of pregnancy on choline-derived methyl donors and related one-carbon metabolites (eg, homocysteine) under conditions of controlled intake and to determine whether maternal choline intake modulates these metabolic variables in maternal, placental, and fetal compartments.
SUBJECTS AND METHODS

Study participants
Third-trimester pregnant (gestational week 27) and nonpregnant control women aged 21 y were recruited from Ithaca, NY, between January 2009 and October 2010 by the use of approved flyers posted at local maternal clinics and at Cornell University. During the screening phase, all study volunteers completed a health history questionnaire that included (if applicable) the date of birth, gestational age at entry into prenatal care, date of last menstrual period, self-reported prepregnancy weight, current gestational age, due date, health status, medication use, vitamin and mineral use, and drug and alcohol use of the volunteer. Entry into this study was contingent on good health status as assessed by a blood chemistry profile, complete blood count, and medical history questionnaire. Additional inclusion criteria were as follows: 1) no tobacco or alcohol product use, 2) no history of chronic disease, 3) normal kidney and liver function, and 4) willingness to comply with the study protocol (ie, eating one meal per day at the on-site location and not consuming foods and beverages outside those provided in the study). Screening participants were excluded if they 1) were carrying more than one fetus, 2) had pregnancy-associated complications (ie, preeclampsia, gestational diabetes, or intrauterine growth restriction), or 3) were taking prescription medications known to affect liver function.
Maternal and newborn information was obtained from medical charts. Maternal information included total weight gained during pregnancy, due date, complications during pregnancy, and complications during labor. Newborn information included the date of delivery, mode of delivery, gestational age, length, weight, head circumference, and Apgar score.
The study protocol was reviewed and approved by the Institutional Review Board for Human Study Participant Use at Cornell University and the Cayuga Medical Center (ie, the hospital where participants delivered their infants; Ithaca, NY). Informed consent was obtained from all participants before entry into the study.
Study design, diet, and supplements
The study was a 12-wk controlled-feeding study in which healthy pregnant women (27 wk gestation; n = 26) with singleton pregnancies and nonpregnant control women (n = 21) consumed 480 or 930 mg choline/d. The 7-d cyclical menu (Table 1) provided an average of 380 mg choline/d with 142 mg from water-soluble forms (free choline, phosphocholine, and glycerophosphocholine) and 236 mg from lipid soluble forms (phosphatidylcholine, sphingomyelin, and lysophosphatidylcholine). Supplemental choline chloride (Balchem) was used to achieve the target intakes and was consumed with a meal chosen by the participant as a single bolus of 100 or 550 mg choline/d. For the period between completion of the 12-wk study and delivery of the infant, pregnant women who had not yet delivered (n = 23) continued to consume their assigned choline supplement (100 or 550 mg choline/d). Maternal blood (at 0, 3, 6, 9, 10, and 12 wk) and urine (at 0, 6, 9, and 12 wk) were collected throughout the consumption phase of the study; a maternal blood sample, placenta tissue, and cord blood were obtained at delivery.
All meals and snacks were prepared in the Human Metabolic Research Unit at Cornell University. Study participants were required to consume at least one meal per day in the metabolic unit Monday through Friday; all other meals, snacks, and beverages were provided as takeaways. The basic menu provided 2100 kcal/d. Energy intake was modified without affecting choline consumption by the addition or subtraction of the following food items: unenriched white rice, snack foods (ie, chips, popcorn, rice cakes, and apples), and certain beverages (ie, soda, lemonade, and apple juice). Weight was obtained weekly to monitor weight gain in pregnant women and weight maintenance in nonpregnant women. The investigators had daily contact with participants throughout the study, which enhanced the compliance of participants to the dietary regimen. In addition, participants were required to verify the consumption of each food item by completing a daily checklist provided by the investigators.
The choline stock solution was prepared every 3 mo by dissolving choline chloride in autoclaved drinking water, filtering the solution through 0.22-lm filters, dispensing it into amber glass bottles, and storing it at 4°C. The molarity of the choline stock solution was determined by using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The variability between choline stock solutions throughout the consumption trials was ,5%. Periodic testing of the choline stock solution during the 3-mo period indicated no degradation. Appropriate volumes of the choline stock solution were dispensed into 50-mL conical tubes, mixed with cranberry-grape juice, and stored at 220°C. The choline cranberrygrape cocktail was thawed 1-2 d before consumption and kept at 4°C
. During the last 6 wk of the study (weeks 6-12), 20% of the total choline intake was provided as deuterated methyl-d9-labeled choline (d9-choline; Cambridge Isotope Laboratories). The administration of labeled choline will allow for future examinations of the activity of the PEMT pathway through isotopomer analysis. The d9-choline stock solution was prepared the same way as the unlabeled choline stock solution and stored at 4°C in amber glass bottles. Appropriate volumes of d9-choline were dispensed into 50-mL conical tubes, mixed with cranberry-grape juice, and stored at 220°C until used for consumption.
A prenatal multivitamin (Pregnancy Plus; Fairhaven Health LLC) and docosahexaenoic acid (200 mg, Neuromins; Nature's Way Products) were provided daily and a potassium and magnesium supplement (General Nutrition Corp) was provided 3 times/ wk to all study participants. Throughout the week, all supplements (including choline) were consumed at the on-site meal chosen by the participant (ie, breakfast, lunch, or dinner) under the supervision of the investigators. For the weekend, participants were asked to consume the supplements with a meal of their choosing and to return all containers and disposables on Monday. Overall, the study protocol was well tolerated with the study regimen completed by 92% of participants (21 of 22 nonpregnant women and 26 of 29 pregnant women). Reasons for stopping the study included nausea (n = 1), early delivery (n = 1), personal challenges (n = 1), and food dislikes (n = 1). Additional information regarding the flow of study participants through the screening and intervention phases is shown in Figure 1 .
Sample collection and processing
Fasting blood samples (10 h) at 0, 3, 6, 9, 10, and 12 wk were collected in one 10-mL serum separator gel and clot-activator tube (SST Vacutainer; Becton, Dickinson and Company), three 10-mL EDTA-coated tubes (Becton, Dickinson and Company), and one 5-mL EDTA-coated tube (Becton, Dickinson and Company). The three 10-mL EDTA-coated tubes containing blood were put on ice immediately after blood collection and centrifuged within 90 min at 1055 · g for 15 min at 4°C. Buffy coat, plasma, and whole blood were removed for genotyping and metabolite measurements as previously described (12, 13) . The SST blood was kept at room temperature, allowed to clot, and centrifuged at 650 · g for 15 min at room temperature. All of the biological samples were dispensed into 1.8-mL cryostat vials (CryoTube; NUNC) and stored at 280°C.
Maternal blood and cord blood samples were also collected. Maternal blood samples were collected into one 10-mL EDTAcoated tube and one 10-mL SST tube at the hospital within 24 h before delivery. Cord blood samples were collected into one 10-mL EDTA-coated tube at the time of delivery. After collection, maternal and cord blood samples were placed on ice (or refrigerated at 4°C) and processed as described previously within 4 h.
The placenta was obtained at delivery and processed at the hospital within 90 min of delivery. After removal of the amnion, 20 full-thickness tissue biopsies (;0.5 · 0.5 · 0.5 cm) were taken from 4 separate locations (ie, the placenta was visually divided into 4 quadrants). Samples were rinsed with phosphatebuffered saline immediately. One sample from each quadrant was randomly selected for RNA extraction, and RNA stabilization solution (Qiagen) was added to prevent RNA degradation. The other samples were flash frozen in liquid nitrogen, placed in a cryostat tube, and stored temporarily in a canister containing liquid nitrogen. In the laboratory, all samples were stored at 280°C until subsequent analyses. Anthropometric measurements of the whole placenta were obtained and included length, width, depth, and weight; weight and length of the umbilical cord were also recorded.
In addition, 24-h urine samples were collected at 0, 6, 9, and 12 wk in amber wide-mouth polyethylene bottles (1 L; Nalgene) that contained 5 g sodium ascorbate. Participants were provided with an insulated bag with ice packs and instructions to keep the urine cold at all times. For each collection, the urine was pooled, the total volume was recorded, and urine was dispensed into five 125-mL narrow-mouth field-sample bottles (ThermoFisher). Aliquots of 1 mL were placed into cryostat vials. All samples were stored at 280°C.
Analytic measurements
Choline content of diet
The choline content of the diet was determined before starting the study and once during the study. Each meal (ie, breakfast, lunch, dinner, or snack), including a beverage, was prepared as for the FIGURE 1. Flow of participants throughout the study screening and intervention phases.
consumption of participants and blended with 150 mL cold 0.1 mol potassium phosphate buffer/L (pH: 6.3) that contained 57 mmol ascorbic acid/L. This mixture was dispensed into 50-mL conical tubes and stored at 280°C. Total choline and betaine contents were determined by the method developed by Koc et al (14) with modifications on the basis of our instrumentation that consisted of a TSQ Quantum mass spectrometer with electrospray ionization source (Thermo) equipped with a refrigerated Accela autosampler (Thermo) and an Accela pump with degasser (Thermo). Extraction and quantification procedures were detailed previously (15) . The average choline and betaine contents of the diet were 380 and 100 mg/d, respectively. Lipid-soluble forms of choline (ie, phosphatidylcholine, lysophosphatidylcholine, and sphingomyelin) accounted for approximately two-thirds of the dietary choline content, and the remaining one-third was derived from water-soluble forms of choline (ie, free choline, phosphocholine, and glycerophosphocholine) ( Table 1) .
Plasma, serum, urine, and tissue measurements LC-MS/MS was used to measure plasma, urinary, and placental concentrations of free choline, betaine, DMG, and acetylcholine (16, 17) with modifications that were based on our instrumentation (18) . Serum and urinary homocysteine, sarcosine, and methionine were quantified by using gas chromatography-mass spectrometry and established protocols (19, 20) .
Because recent findings indicated that the gut microbiome influences choline metabolism and, in turn, the risk of cardiovascular disease (21), blood and urinary trimethylamine N-oxide (TMAO), which is a gut-flora-dependent choline oxidative metabolite, was also measured by using the method of Wang et al (21) with modifications based on our LC-MS/MS instrumentation. Briefly, urine (5 lL) or plasma (50 lL) were mixed with 13 C 3 -TMAO as an internal standard and with acetonitrile that contained 0.1% formic acid to precipitate protein. After samples were mixed by vortex, the samples were centrifuged (10,600 · g for 5 min at 4°C), and the supernatant fluid was transferred to a vial from which 10 lL was injected into the LC-MS/MS system. Metabolites were separated by using HPLC with a Prevail silica column (150 · 2.1 mm, 5 lm; Grace) with a matching guard column (4.6 · 25 mm, 5 lm). The mobile phase was performed under isocratic conditions (500 lL/min) and contained acetonitrile (81%) and ammonium formate (15 mmol/L) with 0.1% formic acid. Analyses were performed by using electrospray ionization in the positive-ion mode with multiple-reaction monitoring of the following transitions: m/z 76.3/58.4 for TMAO, m/z 79.2/61.4 for 13 C 3 -TMAO, and m/z 85.3/66.4 for TMAO-d9. The internal standard, 13 C 3 -TMAO, was synthesized in-house from 13 C 3 -trimethylamine hydrochloride (Sigma) using hydrogen peroxide (22) . Briefly, 30% hydrogen peroxide and 33% of 13 C 3 -trimethylamine hydrochloride solution were mixed (vol:vol of 6:1) and left at room temperature overnight. The mixture was dried, resuspended in water, and tested with LC-MS/MS. Varying amounts of TMAO diluted with water were used to produce standard curves for urinary TMAO quantification. The curves were generated by plotting peak area ratios compared with concentrations. Standard curves of plasma TMAO were constructed by mixing varying amounts of TMAO into control plasma. Mixed TMAO area ratios (measured TMAO area ratios minus endogenous TMAO area ratio) were plotted against mixed concentrations to generate standard curves.
Serum alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were measured by using an automated chemistry analyzer (Dimension Xpand Plus; Siemens Healthcare Diagnostics) at the Human Metabolic Research Unit Clinical Chemistry Laboratory at Cornell University; serum and red blood cell folate were measured microbiologically as previous described (13) .
Choline acetyltransferase transcript abundance
Quantitative real-time reverse transcriptase-polymerase chain reaction was carried out to analyze the expression of choline acetyltransferase (ChAT) in placental tissues. The RNA extraction, reverse transcription, and real-time polymerase chain reaction procedures were conducted as previously described (23) . Forward and reverse primers for ChAT were 5#-TGGACATGATTGAG-CGCTGC-3# and 5#-CGTTCTTGCTGTAGCCTCCG-3#, respectively. Data are expressed as the fold change of the housekeeping gene GAPDH.
Statistical analysis
Forty-seven women (21 nonpregnant and 26 pregnant women) finished the study and were included in the statistical analysis. With the exception of 3 pregnant women at week 12, data were available for every time point (weeks 0, 3, 6, 9, 10, and 12 for blood; weeks 0, 6, 9, and 12 for urine). For week 12, 3 pregnant women (1 woman in the 480-mg choline/d group and 2 women in the 930-mg choline/d group) delivered during the final week of the study. For these participants, the maternal blood sample obtained at delivery was used.
Plots and histograms of the residuals were used to assess normality and variance homogeneity. Data that deviated from the normal distribution (ie, plasma betaine, plasma DMG, serum sarcosine, urinary choline, urinary betaine, urinary DMG, urinary sarcosine, and urinary homocysteine) were logarithmically transformed to achieve normality, and the transformed data were used in subsequent analyses.
To test for baseline (week 0) differences in the dependent variables between pregnant women, nonpregnant women, and cholineintake groups, a 2-factor ANOVA (choline intake and pregnancy) was performed.
To delineate the impact of pregnancy on dependent variables through time, a mixed linear model was constructed for each dependent variable. Because pregnancy is a physiologic state, not a treatment, baseline (week 0) measures of dependent variables were included as a data point. Pregnancy, continuous time (eg, weeks 0, 3, 6, 9, 10, and 12 for plasma variables), and their interaction were included as fixed effects; the sample identifier was included as a random effect. In the initial analysis, choline intake and its interactions with pregnancy and continuous time were also included as fixed effects; however, no 3-way (choline intake · pregnancy · time) or 2-way (choline intake · pregnancy) interactions were detected. Thus, choline intake was not included in the final model.
To delineate the impact of choline intake on the dependent variables, a mixed linear model was constructed for each dependent variable after grouping by pregnancy state. As baseline (week 0) measures may influence the response to choline treatment, measures of the dependent variables at week 0 were included as a covariate. Choline intake, continuous time (eg, weeks 3, 6, 9, 10, and 12 for plasma variables), and their interaction were included as fixed effects; the sample identifier was included as a random effect; the week 0 measure was included as a covariate.
Candidates for entry as covariates into both general linear models were age, BMI, and serum folate at week 0. The covariates that did not achieve a significance of P 0.05 were removed from the models in a stepwise manner.
To test for differences in plasma and urinary TMAO, a 2-factor ANOVA (choline intake and pregnancy) was performed with the change through time (week 12 minus week 0) as the dependent variable and choline intake, pregnancy, and the baseline (week 0) measure as independent variables. To test for differences in the placental and fetal dependent variables, a 1-factor ANOVA (choline intake) was performed. Paired t tests were also performed to compare maternal (at delivery) and fetal corresponding variables.
Data were analyzed with SPSS software (version 19; SPSS Inc). Differences were considered to be significant at P 0.05. Data are presented as means 6 SDs for dependent variables (unless noted otherwise).
RESULTS
Subject characteristics and baseline (week 0) measures
Twenty-six third-trimester pregnant women and 21 nonpregnant women successfully completed the feeding study. The characteristics and baseline (week 0) measures of the final study group stratified by pregnancy and assignment of choline-intake group are shown in Table 2 . The ethnic distribution across choline-intake groups was balanced and reflected the region from which women were recruited. The self-reported prepregnancy BMI of pregnant women did not differ from that of nonpregnant women (P = 0.9). Weights of nonpregnant women were maintained within 68% of initial values. For pregnant women, the average weight gain from weeks 0 to 12 of the study was 6.3 6 2.3 kg (13.9 6 5.1 lb) and did not differ (P = 0.8) between choline-intake groups.
Indicators of liver function (serum alanine aminotransferase and aspartate aminotransferase) and kidney function (serum blood urea nitrogen) were within normal ranges at baseline (Table 1) and throughout the study for all participants (data not shown). Serum total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were 1.3-2.4 times as high (P , 0.001) in third-trimester pregnant women as in nonpregnant women. Serum and red blood cell folate concentrations were well above amounts associated with deficiency (.3 ng/mL for serum folate and .140 ng/mL for red blood cell folate) with greater concentrations in pregnant women (P , 0.01) because of the consumption of a prenatal vitamin that contained folic acid by 85% of the pregnant women before the onset of the study. At baseline, plasma free choline tended to be higher (19%; P = 0.09), whereas plasma betaine, plasma DMG, serum sarcosine, serum homocysteine, and serum methionine were 57%, 44%, 45%, 43%, and 15% lower (P , 0.05), respectively, in thirdtrimester pregnant women than in nonpregnant women. Urinary free choline excretion was higher (P , 0.001) in pregnant women than in nonpregnant women and was closely associated (Pearson's coefficient r = 0.6, P = 0.004) with plasma total cholesterol. Plasma TMAO did not differ between pregnant and nonpregnant women (P = 0.5) but was lower (P = 0.025) in women assigned to the high-choline-intake group. No differences (P . 0.2) in urinary TMAO were detected between assigned choline-intake groups or between pregnant and nonpregnant women.
Effects of pregnancy on blood and urinary biomarkers of choline metabolism
Main effects of pregnancy
Throughout the study, circulating concentrations of choline metabolic biomarkers differed between third-trimester pregnant and nonpregnant women. On average, third-trimester pregnant women had 30% higher (P , 0.001) plasma free choline, 55% lower (P , 0.001) plasma betaine, 38% lower (P , 0.001) plasma DMG, 49% lower (P , 0.001) serum sarcosine, 33% lower (P , 0.001) serum homocysteine, and 13% lower (P , 0.001) serum methionine than did nonpregnant women ( Table 3) .
Urinary excretion of biomarkers of choline metabolism also differed between third-trimester pregnant and nonpregnant women. On average, third-trimester pregnant women excreted 3.3 times as much free choline (P , 0.001), 1.6 times as much betaine (P = 0.019), 1.4 times as much sarcosine (P = 0.01), 1.4 times as much homocysteine (P = 0.004), and 1.7 times as much methionine (P , 0.001) as did nonpregnant women (Table 3) .
After stratification of the cohort by choline intake (ie, 480 or 930 mg choline/d), pregnancy affected choline metabolites (data not shown) in a manner similar to that described in the preceding paragraphs.
Pregnancy · time interactions
Pregnancy interacted with time (P , 0.05) to influence the response of several circulating choline or one-carbon metabolites (ie, free choline, betaine, and homocysteine). In third-trimester pregnant women, circulating concentrations of free choline (P , 0.001; Figure 2A ), betaine (P , 0.001; Figure 2C ) and homocysteine (P , 0.001; Figure 3C ) increased by 13-26% from the beginning (week 0) to the end (week 12) of the study. In contrast, circulating concentrations of free choline (P = 0.9; Figure 2B ) and betaine (P = 0.2; Figure 2D ) did not change in nonpregnant women, and homocysteine decreased (P , 0.001; Figure 3D ) by 16%. The effect of pregnancy on the trajectory of these metabolites during the second half of gestation was consistent with that shown in previous prospective studies (24, 25) . The increase in plasma free choline throughout the third trimester of pregnancy may have been due to enhanced de novo choline synthesis, which is a reaction catalyzed by PEMT. PEMT contains estrogen-response elements, and its expression is induced by estrogen (26) , which increases throughout gestation. Although plasma betaine and serum homocysteine rise throughout the third trimester, both variables remained lower (P , 0.001) than the concentrations observed in nonpregnant control women.
Effects of choline intake on blood and urinary biomarkers of choline metabolism
Third-trimester pregnant women
Compared with the consumption of 480 mg choline/d, the consumption of 930 mg choline/d yielded 13% higher (P = 0.021) plasma choline (Figure 2A ), 25% higher (P = 0.016) plasma betaine ( Figure 2C ), 25% higher (P = 0.012) plasma DMG ( Figure 2E ), and 14% higher (P = 0.07) serum sarcosine ( Figure 3A) . Choline intake did not affect serum homocysteine (P = 0.9; Figure 3C ) or serum methionine (P = 0.3; Figure 3E ).
Choline intake did not affect urinary excretion of free choline (P = 0.3; Figure 4A ), betaine (P = 0.9; Figure 4C ), or DMG (P = 0.1; Figure 4E ). However, compared with 480 mg choline/d, the consumption of 930 mg choline/d yielded 46% higher (P = 0.029) urinary sarcosine ( Figure 5A ) and 37% higher (P = 0.02) urinary methionine ( Figure 5E ). Urinary homocysteine also tended to be higher (45%, P = 0.06) in the 930 mg choline/d-intake group than in the 480 mg choline/d-intake group ( Figure 5C ). These data collectively implied that a higher maternal choline intake enhances the metabolic flux of the methionine cycle, which generates both methionine and homocysteine. 
Nonpregnant women
Compared with the consumption of 480 mg choline/d, the consumption of 930 mg choline/d yielded 11% higher (P = 0.08) plasma choline ( Figure 2B ), 43% higher (P = 0.006) plasma betaine ( Figure 2D ), 37% higher (P = 0.004) plasma DMG ( Figure 2F) , and 46% higher (P = 0.004) serum sarcosine ( Figure 3B ). Choline intake did not affect serum homocysteine (P = 0.2; Figure 3D ) or serum methionine (P = 0.5; Figure 3F ).
Choline intake did not affect the urinary excretion of free choline (P = 0.8; Figure 4B ), betaine (P = 0.6; Figure 4D ), sarcosine (P = 0.3; Figure 5B ), homocysteine (P = 0.7; Figure 5D ), or methionine (P = 0.4; Figure 5F ). However, compared with the consumption of 480 mg choline/d, the consumption of 930 mg choline/d yielded 42% higher (P = 0.005) urinary DMG ( Figure 4F ).
Effects of pregnancy and choline intake on plasma and urinary TMAO
At week 12, plasma TMAO concentration (P = 0.024; Figure  6A ) and urinary TMAO excretion (P = 0.008; Figure 6B ) were higher in the 930-mg choline/d intake group than in the 480-mg choline/d intake group. However, the difference in plasma TMAO between choline-intake groups was mainly driven by 3 of 24 participants. The exclusion of these participants from the statistical analysis attenuated the effects of choline intake on plasma TMAO response (2.9 6 0.5 compared with 2.2 6 0.4 lmol/L; P = 0.07). Pregnancy did not alter plasma TMAO or urinary TMAO excretion and did not interact with choline intake to affect TMAO abundance (data not shown; P . 0.1). Notably, a broad range of plasma TMAO concentrations and urinary TMAO excretions was observed at week 12 with choline intakes of either 480 mg/d (0.7-7.7 lmol/L for plasma TMAO; 1.3-129 mg/d for urinary TMAO) or 930 mg/d (0.6-20.3 lmol/L for plasma TMAO; 0.2-162 mg/d for urinary TMAO excretion). The large interindividual variation in plasma and urinary TMAO under conditions of controlled dietary intake (choline and alternative trimethylamine-containing species) was consistent with individual differences in the composition of colonic microflora. As FIGURE 3. Estimated marginal means (95% CIs) of serum sarcosine, homocysteine, and methionine in third-trimester pregnant (A, C, and E; n = 26) and nonpregnant (B, D, and F; n = 21) women who consumed 480 mg choline/d (n = 13 for pregnant group; n = 11 for nonpregnant group) or 930 mg choline/d (n = 13 for pregnant group; n = 10 for nonpregnant group) for 12 wk. All participants were included in the analysis, and plotted data were estimated by using mixed linear regression models for third-trimester pregnant and nonpregnant women separately as described in the main text. Week 0 for pregnant women was week 27 of gestation. Different superscript letters indicate that the choline metabolite differed (P , 0.05) between cholineintake groups. Serum homocysteine increased throughout the 12-wk study in third-trimester pregnant women (P , 0.001) but decreased in nonpregnant women (P , 0.001). Estimated marginal means (95% CIs) of plasma free choline, betaine, and DMG in third-trimester pregnant (A, C, and E; n = 26) and nonpregnant (B, D, and F; n = 21) women who consumed 480 mg choline/d (n = 13 for pregnant group; n = 11 for nonpregnant group) or 930 mg choline/d (n = 13 for pregnant group; n = 10 for nonpregnant group) for 12 wk. All participants were included in the analysis, and the plotted data were estimated by using mixed linear regression models for third-trimester pregnant and nonpregnant women separately. Week 0 for pregnant women was week 27 of gestation. Different superscript letters indicate that the choline metabolite differed (P , 0.05) between choline-intake groups. In pregnant women, plasma free choline (P , 0.001) and betaine (P , 0.001) increased throughout the 12-wk study; no effect of time (P 0.2) was observed for these metabolites in nonpregnant women. The mean gestational week at birth was 40 wk and did not differ between choline-intake groups. Twenty-seven percent of the newborns were girls, and the sex distribution between groups was balanced. Key fetal and placental variables ( Table 4) were within the normal range and did not differ between cholineintake groups (P . 0.05).
Placental choline and betaine concentrations did not differ (P . 0.05) between choline-intake groups (Table 4) . However, the higher maternal choline intake tended to increase placental acetylcholine accumulation (P = 0.089). To further elucidate the effects of maternal choline intake on acetylcholine metabolism, we examined the messenger RNA abundance of ChAT, which catalyzes the synthesis of acetylcholine from choline. We showed that transcript abundance was elevated (P = 0.022) in the 930 mg choline/d-intake group, which suggests that higher maternal choline intake enhances the placental synthesis of acetylcholine that may in turn facilitate amino acid transport, cellular differentiation, and parturition (27, 28) . DMG was not detected in the placental tissue.
Consistent with previous reports (29, 30) , cord plasma choline was 4.4 times as high (35 6 10 compared with 8 6 2 lmol/L, respectively; P , 0.001) and cord plasma betaine was 3 times as high (30 6 7 compared with 10 6 5 lmol/L, respectively; P , 0.001) as maternal plasma concentrations at delivery. However, in contrast to previous work that showed higher circulating DMG in cord plasma than in maternal plasma (29) (30) (31) , we showed 29% lower circulating DMG in cord plasma than in maternal plasma (2.0 6 1.0 compared with 2.8 6 1.0 lmol/L, respectively; P , 0.001). Maternal plasma DMG in the current study was ;56% higher than shown in previous findings (28, 29) , possibly due to supplementation of the maternal diet with extra choline (ie, 100 or 550 mg choline/d).
Although maternal choline intake did not affect concentrations of choline or betaine in cord venous plasma (P . 0.1), the higher maternal choline intake (930 compared with 480 mg choline/d) . Estimated marginal means (95% CIs) of urinary sarcosine, homocysteine, and methionine in third-trimester pregnant (A, C, and E; n = 26) and nonpregnant (B, D, and F; n = 21) women who consumed 480 mg choline/d (n = 13 for pregnant group; n = 11 for nonpregnant group) or 930 mg choline/d (n = 13 for pregnant group; n = 10 for nonpregnant group) for 12 wk. All participants were included in the analysis, and plotted data were estimated by using mixed linear regression models for third-trimester pregnant and nonpregnant women separately as described in the main text. Week 0 for pregnant women was week 27 of gestation. Different superscript letters indicate that the choline metabolite differed (P , 0.05) between choline-intake groups. led to a doubling of cord plasma DMG (P = 0.002; Table 4 ), which is the metabolite produced when choline is used as a methyl donor.
DISCUSSION
This highly controlled feeding study sought to quantify the effects of pregnancy and maternal choline intake on maternal and fetal biomarkers of choline metabolism. The following 2 main findings emerged: 1) pregnancy markedly altered biomarkers of choline metabolism and 2) a higher maternal choline intake increased the use of choline as a methyl donor in both maternal and fetal compartments.
Circulating choline-derived methyl donors were markedly lower in third-trimester pregnant women than in nonpregnant women
In the current study with controlled choline intake, plasma betaine and DMG were 40-55% lower in third-trimester pregnant than in nonpregnant women, which is a result that is consistent with previous observational reports (24, 29, 30) . We also report, for the first time to our knowledge, that serum sarcosine was 49% lower in third-trimester pregnant women than in nonpregnant women. Although hemodilution can contribute to reductions in circulating metabolites during pregnancy, the expansion of maternal plasma could not fully explain the lower concentrations of these methyl donors. Maternal plasma volume begins to increase at week 10 of gestation and expands an average of 45% to provide for the greater circulatory needs of the maternal and fetal organs (32) . As such, hemodilution would be expected to yield a 30% reduction in the circulating metabolites but not the observed 40-55% reduction.
An additional explanation for the results was the increased use of choline-derived methyl groups by pregnant women. Accelerations in one-carbon metabolism transpire during pregnancy to support cellular proliferation (eg, nucleotide biosynthesis) and the establishment of epigenetic methylation marks on newly formed cells (33) . After the use of betaine as a methyl donor in the formation of the S-adenosylmethionine precursor methionine, the methyl groups associated with DMG and subsequently methylglycine (sarcosine) are used in folate-mediated one-carbon metabolism for the synthesis of purines, thymidylate, or methionine.
Notably, mean serum folate concentrations were elevated (ie, .20 ng/mL) in pregnant women at baseline (week 0) and throughout the study because of the consumption of a folic acidcontaining prenatal vitamin by the women. Thus, although folate and choline are highly interrelated, the diminished circulating FIGURE 6 . Scatter plot of the change (week 12 minus week 0) in plasma TMAO concentration (A) and urinary TMAO excretion (B) in third-trimester pregnant (n = 26) and nonpregnant (n = 21) women who consumed 480 mg choline/d (n = 13 for pregnant group; n = 11 for nonpregnant group) or 930 mg choline/d (n = 13 for pregnant group; n = 10 for nonpregnant group) for 12 wk. Data were analyzed by using 2-factor ANOVA with the change through time as the dependent variable and choline intake, pregnancy, and the baseline measure (week 0) as independent variables. TMAO, trimethylamine N-oxide. concentrations of choline-derived methyl donors in folatereplete pregnant women suggest that extra folate (ie, folic acid) cannot compensate for the higher use of choline as a methyl donor, which may be because folate is predominately a carrier of methyl groups, whereas choline is a source.
Obligatory losses of urinary choline and betaine were ;2-4 times as high in pregnant women Pregnant women excreted ;4 times as much free choline as did nonpregnant women at baseline (week 0) and throughout the study. A greater excretion of free choline has also been shown in hyperlipoproteinemic adults (34) , which is a condition that transpires during pregnancy (35) . Because lipoproteins contain phosphatidylcholine, the greater urinary excretion of free choline by pregnant women (relative to nonpregnant women) may have been a consequence of enhanced uptake and catabolism of lipoproteinderived phosphatidylcholine in the kidneys. The relatively strong relation between the urinary excretion of free choline and serum total cholesterol at week 0 (Pearson's coefficient r = 0.6, P = 0.004) and week 12 (r = 0.4, P = 0.016) was consistent with this metabolic scenario.
To the best of our knowledge, this is the first report of greater urinary betaine excretion in pregnant than in nonpregnant women. Normally, only small amounts of betaine are excreted in the urine. However, during pregnancy, the marked increase in plasma volume and glomerular filtration likely contributed to urinary loss of betaine in third-trimester pregnant women that was 2 times as high as that in nonpregnant women.
The markedly diminished circulating concentrations of choline-derived methyl donors in pregnant women coupled with their greater urinary excretion of choline and betaine (;13 mg/d when expressed as a choline equivalent) implies that an increment of 25 mg choline/d (450 compared with 425 mg choline/d) is insufficient to meet the choline demands of pregnancy.
A higher maternal choline intake resulted in enhanced use of choline as a methyl donor A higher choline intake resulted in the greater maternal use of choline as a methyl donor as evidenced by the higher concentrations of DMG and sarcosine (intermediates formed in the demethylation of choline). Higher concentrations of DMG and sarcosine on the higher choline intake were also consistent with an increased availability of carbons for folate-mediated onecarbon metabolism. The higher intake did not alter the urinary excretion of free choline and betaine, which implies that a doubling of the choline AI does not exceed the cells' capacity to use the extra choline as a methyl donor.
Although maternal choline intake did not influence neonatal circulating concentrations of free choline or betaine, DMG was 2 times as high in the neonates of mothers who consumed 930 mg choline/d as in the neonates of those who consumed 480 mg choline/d. Because DMG was not detected in placental tissue samples, the DMG in fetal circulation was most likely of fetal origin and generated on the use of choline or betaine as methyl donors. To the best of our knowledge, this is the first human study to show an effect of maternal choline intake on neonatal biomarkers of choline metabolism.
Choline-derived methyl groups are needed for DNA methylation, which is essential for developmental processes including genomic imprinting and the maintenance of genome stability (36) . The increased fetal and maternal use of choline as a methyl donor in the 930 compared with 480 mg choline/d-intake group likely had functional consequences that were mediated through epigenetic mechanisms. The genomic consequences of the higher choline intake are currently being explored via measurements of placental and blood leukocyte DNA methylation (global and site specific) as well as gene-expression analyses.
In conclusion, third-trimester pregnant women have substantially lower circulating concentrations of choline-derived methyl donors even under folate-replete conditions. Coupled with their increased obligatory loss of urinary choline and betaine (;13 mg/d as choline equivalents), these data suggest that an additional 25 mg choline/d is insufficient to meet the choline demands of third-trimester pregnant women. Moreover, the study findings showed that maternal choline intake modifies both maternal and fetal biomarkers of choline metabolism with evidence of greater use of choline as a methyl donor on a higher choline intake.
